2017 American Transplant Congress
Personalized Tacrolimus (TAC) Dosing Using Genetic Variants in Caucasian Kidney Transplant (Tx) Recipients.
TAC is an immune suppressant with a narrow therapeutic index and high pharmacokinetic (PK) variability leading to uncertainty in blood concentrations. We previously developed an…2017 American Transplant Congress
Benefits of Mycophenolate Sodium Over Mycophenolate Mofetil in Renal Transplant Patients Carrying UGT1A9 Polymorphism.
Nephrologist, Hospital Clínico San Carlos, Madrid, Spain
Aims: To analyze the differences in mycophenolic acid (MPA) pharmacokinetics and digestive side effects in renal transplant recipients on treatment with Mycophenolate mofetil (MMF) and…2017 American Transplant Congress
An Analysis of Tacrolimus XL Dosing in Obese Kidney Transplant Recipients.
Background:Tacrolimus extended-release (XL) is utilized in many immunosuppressive regimens post-kidney transplantation. Current dosing recommendation for the XL formulation in renal transplant (txp) is 0.15 mg/kg/day…2016 American Transplant Congress
Mycophenolate Mofetil Single Dose Pharmacokinetics Following Laparoscopic Sleeve Gastrectomy.
The influence of various metabolic surgery procedures on immunosuppressant pharmacokinetics (PK) is largely unknown. For laparoscopic sleeve gastrectomy (LSG) (currently the most common procedure) no…2016 American Transplant Congress
Patients with ESRD Due to Diabetes Have Higher Variability of Their Tacrolimus Levels and Worse Outcomes.
Imperial College Renal and Transplant Centre, Imperial College NHS Trust, London, United Kingdom.
IntroductionNonadherence to immunosuppressants is associated with rejection and graft loss and nonadherence to antidiabetics is associated with poor glycaemic control leading to microvascular complications and…2016 American Transplant Congress
Tacrolimus Dosing, Trough Concentrations and Dose Adjustments Compared Between Two Generic Formulations in Adult Kidney Transplant Recipients.
Objective: The aim of this study was to assess if changing between two different formulations of generic tacrolimus ([tac] Mylan® and Dr. Reddy's Lab®) impacts…2016 American Transplant Congress
Evaluating the Influence of Liver Donor and Recipient Race on Tacrolimus Dose Requirements.
Einstein Medical Center, Philadelphia, PA.
Background: The majority of liver transplant recipients (LTR) receive tacrolimus (TAC) to prevent allograft rejection. Early establishment of therapeutic levels is imperative to efficacy. Several…2016 American Transplant Congress
Nuclear Factor of Activated T-Cells Post-Renal Transplant.
Background: Nuclear Factor of Activated T-cells (NFAT1) is a transcription factor regulating the expression of key targets involved with cellular immune function. Calcineurin is a…2016 American Transplant Congress
Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.
Pharmacokinetic (PK) data show reduced mycophenolic acid levels in transplant recipients taking mycophenolate mofetil (MMF) and proton pump inhibitors (PPIs) concomitantly. MMF dosing is not…2016 American Transplant Congress
Late Renal Allograft Rejection Is Predicted by High Intrapatient Variability of Tacrolimus Levels.
Imperial College Renal and Transplant Centre, Imperial College NHS Trust, London, United Kingdom.
IntroductionNonadherence to immunosuppressive medication is associated with rejection and graft loss. We have previously shown that intrapatient variability (IPV) of tacrolimus trough levels between 6-12…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- Next Page »